Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising.
- Quantum BioPharma executive co-chairman and co-founder Anthony Durkacz appeared as a guest on the BioMedWire Podcast.
- Durkacz outlined the company’s strategy for advancing Lucid-MS, the company’s lead drug candidate for multiple sclerosis.
- The Quantum BioPharma exec also provided an update on unbuzzd, the company’s innovative, clinically validated alcohol metabolism accelerator designed to help sober people up faster.
Executive thought leadership has become an increasingly important component of corporate communications, particularly in highly specialized industries such as biotechnology. Through podcasts, interviews and other educational forums, company leaders can explain complex technologies, discuss development strategies and provide context that is often difficult to capture in traditional press releases. That approach was recently on display when Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) executive co-chair and co-founder Anthony Durkacz appeared as a guest on the BioMedWire Podcast.
Quantum BioPharma is a biopharmaceutical company focused on developing treatments for neurodegenerative, metabolic and alcohol-misuse disorders, with Lucid-MS and its ownership in commercially product unbuzzd(TM). During the interview, Durkacz outlined the company’s strategy for advancing Lucid-MS, the company’s lead drug candidate for multiple sclerosis (“MS”); discussed the market opportunity for unbuzzd; and reviewed key objectives planned for this year.
Durkacz focused much of the discussion on Lucid-MS. Explaining the rationale behind the program, he noted that “Quantum BioPharma is focused on a drug candidate that is trying to address an issue that exists today for people that suffer from multiple sclerosis.” He went on to describe the progressive nature of the disease and the debilitating impact it can have on mobility and quality of life.
“What our main drug candidate focus, Lucid-MS, is trying to do is reverse damage that’s been done to people’s mobility,” he stated, noting that almost three million people are diagnosed with MS worldwide with almost one million in the USA. “We believe that is something that is not addressed in any drug or therapy today in the world.”
The podcast discussion also covered the company’s development plans for Lucid-MS, which includes an upcoming clinical trial. “We filed our IND for a phase 2 trial for MS patients,” Durkacz explained. Once approved, “This will be the first time that Lucid-MS would be taken by a person with MS.”
“This will be the first time we will be able to see the reaction . . . and determine whether there are any efficacy signals that match what we’ve seen in our animal models over the past decade,” he continued. “That is what we are laser focused on right now.” The advancement into patient studies marks an important milestone for the program as the company seeks to gather additional data regarding safety and potential life changing therapeutic effects.
In addition to discussing its therapeutic pipeline, the Quantum BioPharma exec used the interview to provide an update on unbuzzd, a product the company developed that has been licensed and was designed and clinically proven to accelerate alcohol metabolism. Durkacz explained that the product is already commercially available in the United States and forms part of the company’s broader strategy of building value through both clinical-stage biotechnology assets and commercial opportunities. The combination of therapeutic development programs and commercial products gives the company exposure to multiple potential growth drivers while advancing its longer-term pharmaceutical objectives.
Durkacz and podcast host Stuart Smith also discussed the company’s broader mission. The company is focused on developing innovative solutions for challenging neurodegenerative and metabolic disorders as well as alcohol-misuse conditions. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum BioPharma continues to advance Lucid-MS. Meanwhile, the company maintains an ownership interest in unbuzzd Wellness Inc. and continues to participate in the commercial growth of the unbuzzd brand.
The BioMedWire Podcast focuses on conversations with executives and industry experts involved in pharmaceutical and biotechnology innovation. The format provides an opportunity for management teams to discuss scientific programs, business strategies and industry trends in greater detail than is typically possible through standard corporate communications.
As biotechnology continues to become increasingly complex and competitive, educational platforms such as podcasts are emerging as valuable tools for corporate communication. For companies developing novel therapies, direct discussions with knowledgeable executives can help investors, industry observers and potential partners gain a deeper understanding of both the science and the business strategy behind emerging innovations. Quantum BioPharma’s recent BioMedWire appearance illustrates how executive engagement can complement traditional investor relations efforts while providing a more detailed look at the company’s research programs, commercial initiatives and anticipated milestones for the year ahead.
For more information, visit www.QuantumBioPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
